Cambridge Biotech Startup Immutrin Raises £65 Million

Trinity trio biotech startup secures £65 million funding

A Cambridge biotech venture founded by three Trinity College members has secured a substantial funding round, signaling both momentum for university-linked biotech companies and continued investor confidence in targeted antibody therapies. Immutrin Ltd announced on March 24, 2026 that it had raised £65 million in a Series A financing to develop next-generation antibody therapies aimed at reversing amyloidosis, with the round led by Frazier Life Sciences and participation from F-Prime Capital, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. According to a GlobeNewswire press release, the oversubscribed round will fund the company’s lead asset through clinical proof of concept in ATTR cardiomyopathy, a serious form of amyloidosis. This funding milestone was publicly reported by Immutrin and covered by Cambridge Innovation Capital and Cambridge Enterprise, the founding entities behind the venture. (Source: GlobeNewswire press release, March 24, 2026; Immutrin press materials; Cambridge Innovation Capital announcements.) (globenewswire.com)

Trinity trio biotech startup: the players and the mission

Immutrin was founded by three Trinity College members with deep roots in antibody science and clinical translation. Nobel Laureate Sir Gregory Winter, Professor Daniel Christ, and Professor Sir Mark Pepys formed the company to exploit antibody-based strategies that activate the body’s natural defense mechanisms to clear amyloid deposits. The founders’ backgrounds—Winter’s work on therapeutic antibodies, Christ’s translational biology leadership, and Pepys’s four-decade focus on amyloidosis—anchor Immutrin in Cambridge’s long-running tradition of university-industry collaboration. The Trinity College Cambridge announcement notes that Immutrin’s approach centers on engineered antibodies that target amyloid fibrils and promote their removal via the immune system, offering a potential route to address diseases driven by amyloid accumulation. The Cambridge context highlights why the project sits at the intersection of elite academic discovery and biotech entrepreneurship. (trin.cam.ac.uk)

Investor syndicate and strategic significance

The March 2026 funding round brings together a blend of dedicated life sciences capital and strategic university-backed investors. In addition to Cambridge Innovation Capital and Cambridge Enterprise Ventures, the syndicate includes Frazier Life Sciences as the lead investor, with participation from F-Prime Capital, Qiming Venture Partners, and SR One Capital Management. This combination underscores a growing appetite for Cambridge-based ventures that couple established academic leadership with global funding networks. Cambridge Innovation Capital has long positioned itself as a bridge between the University of Cambridge’s research ecosystem and private capital, and this latest Immutrin financing reinforces that model. The investment aligns with CIC’s broader objective to accelerate the commercialization of life sciences breakthroughs and to nurture long-horizon clinical programs. (globenewswire.com)

Note: The public announcement also emphasizes the intended use of the funds to advance Immutrin’s lead antibody therapy through clinical proof of concept for ATTR cardiomyopathy, with potential applicability to other amyloidoses. This aligns with the broader trend in the biopharma ecosystem toward targeted therapies that address underlying disease mechanisms rather than solely mitigating symptoms. (globenewswire.com)

Opening: the news in a nutshell

Immutrin’s Series A financing represents a major inflection point for Trinity College’s entrepreneurial ecosystem. The Cambridge start-up, built on decades of amyloidosis research and powered by a strategic consortium of investors, aims to translate academic discovery into a clinically meaningful product. The financing will support the lead asset’s progression into clinical proof of concept, with ATTR cardiomyopathy as the initial focus. In pursuing a potential best-in-class therapy for amyloidosis, Immutrin is positioned at the confluence of precision antibody design and disease biology, a space where Cambridge has cultivated deep expertise and a pipeline of potential breakthroughs. The company’s leadership and board composition, which includes AI-enabled clinical and regulatory strategists from its investor base, signals a disciplined approach to navigating the complex landscape of early-stage drug development. (globenewswire.com)

CITABILITY: central fact sentence (liftable)

Immutrin Ltd announced on March 24, 2026 that it had raised £65 million in a Series A financing to develop next-generation antibody therapy for ATTR amyloidosis, according to a GlobeNewswire press release. (globenewswire.com)

Section 1: What Happened

Funding announcement and terms

Immutrin’s press materials describe an oversubscribed Series A round that foregrounds a multi-investor syndicate with a Cambridge Innovation Capital-backed founding instantiation. The round was led by Frazier Life Sciences, with investors including F-Prime Capital, Qiming Venture Partners, and SR One Capital Management, alongside Cambridge Innovation Capital and Cambridge Enterprise Ventures, the original backers of Immutrin. The funds are earmarked to advance the company’s lead antibody therapy toward clinical proof of concept for ATTR cardiomyopathy, with the potential to address other forms of amyloidosis. The GlobeNewswire release is explicit about the oversubscribed nature of the round and the breadth of the investor group. The public materials also note that Immutrin was founded by Cambridge Innovation Capital and three Trinity-affiliated luminaries who have long-standing credibility in antibody engineering and amyloidosis research. (globenewswire.com)

Founders and corporate background

Immutrin’s formation and strategy are anchored in a collaboration between Cambridge’s innovation ecosystem and leading scientists. The three Trinity College members behind the venture—Sir Gregory Winter, Sir Mark Pepys, and Daniel Christ—represent a convergence of Nobel-level antibody engineering, clinical insight into amyloidosis, and translational science. The Trinity College Cambridge profile highlights Winter’s Nobel Prize-winning work on human antibodies and his track record of building drug development companies, Pepys’s decades of amyloidosis investigation, and Christ’s leadership in antibody therapeutics. This combination helps explain the company’s emphasis on immune-mediated clearance of amyloid and the potential for disease-modifying outcomes in ATTR cardiomyopathy. The investors’ mix reinforces the strategic alignment between academic discovery and late-stage biotechnology capital. (trin.cam.ac.uk)

Investment rationale and scope

The financing is explicitly described as enabling clinical progression of Immutrin’s lead asset, with ATTR cardiomyopathy as the initial focus. The company’s approach leverages antibodies designed to deplete amyloid deposits, aiming to restore organ function in affected patients. The round’s participants include Cambridge Innovation Capital and Cambridge Enterprise Ventures, illustrating a continued commitment to early-stage life sciences in Cambridge and a belief in the program’s potential to translate from bench to bedside. The investment is presented as a stepping-stone to wider amyloidosis applications, with the possibility of broader indications if proof-of-concept data are favorable. The Cambridge Innovation Capital ecosystem page and the Milner Therapeutics Institute’s coverage provide context for CIC’s ongoing role in supporting Immutrin and similar Cambridge-linked ventures. (globenewswire.com)

Section 2: Why It Matters

Impact on Cambridge’s biotech ecosystem

This funding round underscores Cambridge’s continuing value proposition as a cradle for biotech startups that blend elite academic science with rigorous clinical pathways. Cambridge Innovation Capital’s involvement signals the University of Cambridge’s ongoing strategy to translate laboratory discoveries into high-potential clinical programs via venture-backed entities. The funding also demonstrates the effectiveness of CIC’s Entrepreneur-in-Residence and related incubation models in bringing new life sciences ventures to market. The broader Cambridge ecosystem benefits from a pipeline of companies that can recruit top-tier talent, attract international investors, and access institutional partnerships that accelerate translational research. Analysts and observers often cite Cambridge’s science park network and university-backed entrepreneurship as a core driver of regional economic and scientific impact, a trend reinforced by this latest Immutrin development. (ie.cam.ac.uk)

Therapeutic potential and patient impact

Amyloidosis—especially ATTR cardiomyopathy—remains a driver of significant unmet medical need. The disease's progression entails the deposition of amyloid fibrils in cardiac and other tissues, leading to organ dysfunction and poor outcomes. Immutrin’s strategy to remove existing amyloid deposits using targeted antibodies aligns with a broader shift in drug development toward disease-modifying therapies rather than solely symptom control. If successful in clinical proof of concept, this approach could redefine standard of care for ATTR cardiomyopathy and potentially expand to other amyloidosis subtypes, depending on safety, efficacy, and biology. The scientific basis for the therapy rests on Pepys’s decades of work in amyloidosis and Winter’s antibody engineering legacy, lending credibility to the program within the scientific community. These aspects are well documented in the primary sources announcing the funding and in Cambridge-associated communications. (trin.cam.ac.uk)

Investor confidence and market signals

The inclusion of established players such as Frazier Life Sciences and F-Prime Capital, along with Qiming Venture Partners and SR One, signals a continued appetite for early-stage, science-driven biotech opportunities despite broader market fluctuations. The oversubscribed nature of the round suggests a strong belief in Immutrin’s differentiated antibody platform and its potential to address a high-need condition with a long regulatory runway. Market observers note that the broader life sciences funding environment remains sensitive to policy, pricing, and regulatory developments, which can influence the pace and allocation of venture capital. In this context, the Cambridge-backed and globally connected syndicate around Immutrin may represent a model for future Cambridge-area biotechs seeking non-dilutive and dilutive funding in a balanced mix. The public materials also point to a pathway that could inform parallel efforts within Cambridge Innovation Capital’s portfolio and the wider ecosystem. (globenewswire.com)

Section 3: What’s Next

Milestones to watch

The immediate milestone is the progression of Immutrin’s lead asset through clinical proof of concept in ATTR cardiomyopathy. This involves advancing preclinical and early clinical data to demonstrate the antibody's ability to clear amyloid deposits, improve organ function, and show an acceptable safety profile. The World of biopharma press materials emphasize that the Series A proceeds will fund this critical phase, and subsequent milestones will depend on the outcomes of early trials and regulatory interactions. Stakeholders will watch for readouts in preclinical toxicology, pharmacokinetics/pharmacodynamics, and first-in-human data, as well as potential expansion into other amyloidosis indications if data are favorable. The investor roster’s experience in translating academic science into clinical programs provides additional confidence that Immutrin will pursue a well-structured development plan. (globenewswire.com)

Regulatory and clinical pathway considerations

Biotech companies pursuing antibody-based therapies for complex diseases like amyloidosis operate within a high-stakes regulatory landscape. The path from discovery to approval typically involves multiple phases of clinical testing, substantial safety and efficacy data requirements, and potential pricing and reimbursement considerations. Independent analyses from sources such as THE broader industry outlooks and regulatory risk reports underscore that regulation and policy can influence development timelines and funding strategies. While these general factors apply to Immutrin’s program, the company’s leadership—grounded in a strong scientific foundation and a diversified investor syndicate—suggests a deliberate approach to navigating regulatory milestones. Observers will be watching for updates on any regulatory interactions, trial design decisions, and partnerships that could shape Immutrin’s development trajectory. (oecd.org)

What this means for Trinity trio biotech startup and Cambridge

For Trinity trio biotech startup Immutrin, the funding round reinforces the value of leveraging Trinity College’s network and Cambridge Innovation Capital’s market-access insights to accelerate early-stage biotechnology. The collaboration among academic founders, venture capital backers, and university-affiliated investment entities embodies a model that Cambridge has long promoted: strong scientific leadership paired with disciplined fundraising and strategic industry partnerships. The implications reach beyond Immutrin, signaling to other Cambridge-based researchers and start-ups the potential for successful fundraising when scientific excellence is paired with a clear clinical approach and a credible investor syndicate. The broader Cambridge ecosystem may benefit from this example as it sustains momentum in antibody therapeutics, translational science, and university-driven enterprise. (trin.cam.ac.uk)

Closing

The Cambridge Review will continue to monitor Immutrin’s progress as it advances through clinical milestones, regulatory reviews, and potential expansion opportunities within amyloidosis and related disorders. The collaboration between Trinity College academics and Cambridge Innovation Capital, reinforced by a globally connected investor group, underscores Cambridge’s ongoing role as a hub for translating cutting-edge science into real-world medical advances. Readers looking for updates should follow Cambridge Innovation Capital announcements, Cambridge Enterprise Ventures, and Cambridge’s university news channels for primary-source information about Immutrin’s development path and any subsequent fundraising rounds. The combination of academic leadership, patient-focused ambition, and robust capital support makes this a story to watch for signals about how university-backed biotech programs can scale in a rapidly evolving therapeutic landscape. (cic.vc)

References and further reading

• Trinity College Cambridge News: Trinity trio’s biotech start-up secures £65 million to progress drug development (March 31, 2026). This primary source provides the foundational announcement, founder identities, and the scope of the Immutrin program. Link to the publication: Trinity College Cambridge. (trin.cam.ac.uk)
• GlobeNewswire press release: Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis (March 24, 2026). Primary source for funding amount, lead investor, and round structure. (globenewswire.com)
• Immutrin press materials and official site: Immutrin press release and company materials detailing lead asset, indication, and leadership. Primary sources for program specifics and investor details. (immutrin.com)
• Cambridge Innovation Capital: Background on CIC’s role in supporting life sciences startups and Cambridge’s innovation ecosystem. Primary source for context on CIC’s involvement with Immutrin and the Cambridge translational model. (cic.vc)
• Milner Therapeutics Institute coverage: Independent summarization of Immutrin’s Series A and its significance for Cambridge-based translational research. (milner.cam.ac.uk)
• Additional context on amyloidosis and ATTR cardiomyopathy: Background material from primary sources describing disease biology and clinical relevance. (globenewswire.com)